Stockscreener 앱 받기
0.80
4.71%
-0.05
전일 마감가:
$0.85
열려 있는:
$0.87
하루 거래량:
130.22K
Relative Volume:
1.17
시가총액:
$4.91M
수익:
-
순이익/손실:
$-33.44M
주가수익비율:
-0.0499
EPS:
-16.0242
순현금흐름:
$-28.30M
1주 성능:
-36.72%
1개월 성능:
-11.15%
6개월 성능:
-59.09%
1년 성능:
-86.46%
1일 변동 폭
$0.75
$0.888
1주일 범위
$0.75
$1.33
52주 변동 폭
$0.6911
$10.79
Nucana Plc Adr Stock (NCNA) Company Profile
NCNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NCNA
Nucana Plc Adr
|
0.805 | 4.91M | 0 | -33.44M | -28.30M | -16.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.53 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
581.02 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
556.38 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.50 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
239.50 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Nucana Plc Adr Stock (NCNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-03 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-10-22 | 개시 | Truist | Buy |
| 2020-07-24 | 개시 | Oppenheimer | Outperform |
| 2019-08-19 | 개시 | H.C. Wainwright | Buy |
| 2018-10-19 | 개시 | Piper Jaffray | Overweight |
| 2017-10-23 | 개시 | Citigroup | Buy |
| 2017-10-23 | 개시 | Jefferies | Buy |
| 2017-10-23 | 개시 | William Blair | Outperform |
모두보기
Nucana Plc Adr 주식(NCNA)의 최신 뉴스
Stock Update - Investorsobserver
NuCana Reports Strong Phase 2 Data: 75% Disease Control in Melanoma Trial, Lower Q3 Loss - StockTitan
Get in on NuCana plc ADR’s (NCNA) buy-in window today! - SETE News
NuCana plc ADR Inc. (NCNA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
NuCana secures new US patent for cancer treatment NUC-7738 - Investing.com India
Market Watch: NuCana plc ADR (NCNA)’s Noteworthy Drop, Closing at 3.05 - The Dwinnex
Daily Market Movement: NuCana plc ADR (NCNA) Sees a -7.03 Decrease, Closing at 3.44 - The Dwinnex
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study - Yahoo Finance
NCNA’s Financial Health: Exploring NuCana plc ADR’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
NuCana price target lowered to $25 from $150 at Oppenheimer - TipRanks
Oppenheimer slashes NuCana stock target, remains Outperform on optimism for upcoming trials - Investing.com
NuCana Ends Phase 2 Cancer Study, Focuses on Promising Treatments - TipRanks
NuCana shares receive $150 stock PT at Oppenheimer on upbeat trial prospects - Investing.com
NuCana plc Announces Reverse ADS Split - TipRanks
NuCana: Potential Turnaround In 2024 But Risky - Seeking Alpha
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
Will NuCana Continue to Surge Higher? - Nasdaq
NuCana (NCNA) Stock Price, News & Analysis - MarketBeat
Nucana Plc Adr (NCNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.65%
0.06%
자본화:
|
볼륨(24시간):